Cargando…

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies

Chronic lymphocytic leukemia (CLL) is an indolent but incurable disease. Despite the improvement of the available therapies, the management of heavily-treated CLL patients represents a challenge for modern practitioners. Ofatumumab is a second-generation, fully human anti-CD20 monoclonal antibody th...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo, Jorge, Perez, Kimberly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262337/
https://www.ncbi.nlm.nih.gov/pubmed/22282677
_version_ 1782221707504779264
author Castillo, Jorge
Perez, Kimberly
author_facet Castillo, Jorge
Perez, Kimberly
author_sort Castillo, Jorge
collection PubMed
description Chronic lymphocytic leukemia (CLL) is an indolent but incurable disease. Despite the improvement of the available therapies, the management of heavily-treated CLL patients represents a challenge for modern practitioners. Ofatumumab is a second-generation, fully human anti-CD20 monoclonal antibody that has shown activity in CLL patients who have failed very effective therapies such as fludarabine, alemtuzumab and rituximab. Potential benefits of ofatumumab include powerful complement-dependent cytotoxicity, less immunogenicity, faster infusions and activity in resistant CLL patients. Recently, the FDA has approved ofatumumab for the treatment of CLL patients who have failed fludarabine and alemtuzumab-based regimens. The aim of this review is to summarize the current knowledge regarding pharmacology, mechanism of action, pre-clinical and clinical development, and the role of ofatumumab for the treatment of CLL patients who have failed previous therapies. Further research is necessary to further define the role of ofatumumab in the treatment of CLL.
format Online
Article
Text
id pubmed-3262337
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32623372012-01-26 The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies Castillo, Jorge Perez, Kimberly J Blood Med Review Chronic lymphocytic leukemia (CLL) is an indolent but incurable disease. Despite the improvement of the available therapies, the management of heavily-treated CLL patients represents a challenge for modern practitioners. Ofatumumab is a second-generation, fully human anti-CD20 monoclonal antibody that has shown activity in CLL patients who have failed very effective therapies such as fludarabine, alemtuzumab and rituximab. Potential benefits of ofatumumab include powerful complement-dependent cytotoxicity, less immunogenicity, faster infusions and activity in resistant CLL patients. Recently, the FDA has approved ofatumumab for the treatment of CLL patients who have failed fludarabine and alemtuzumab-based regimens. The aim of this review is to summarize the current knowledge regarding pharmacology, mechanism of action, pre-clinical and clinical development, and the role of ofatumumab for the treatment of CLL patients who have failed previous therapies. Further research is necessary to further define the role of ofatumumab in the treatment of CLL. Dove Medical Press 2010-02-25 /pmc/articles/PMC3262337/ /pubmed/22282677 Text en © 2010 Castillo and Perez, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Castillo, Jorge
Perez, Kimberly
The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
title The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
title_full The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
title_fullStr The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
title_full_unstemmed The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
title_short The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
title_sort role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262337/
https://www.ncbi.nlm.nih.gov/pubmed/22282677
work_keys_str_mv AT castillojorge theroleofofatumumabinthetreatmentofchroniclymphocyticleukemiaresistanttoprevioustherapies
AT perezkimberly theroleofofatumumabinthetreatmentofchroniclymphocyticleukemiaresistanttoprevioustherapies
AT castillojorge roleofofatumumabinthetreatmentofchroniclymphocyticleukemiaresistanttoprevioustherapies
AT perezkimberly roleofofatumumabinthetreatmentofchroniclymphocyticleukemiaresistanttoprevioustherapies